The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wooley, P. H.
Right arrow Articles by Gillis, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wooley, P. H.
Right arrow Articles by Gillis, S.

The Journal of Immunology, Vol 151, Issue 11 6602-6607, Copyright © 1993 by American Association of Immunologists

ARTICLES

Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice

PH Wooley, J Dutcher, MB Widmer and S Gillis
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201.

A recombinant human TNF receptor Fc fusion protein (rhuTNFR:Fc) was assessed for antiarthritic activity using murine type II collagen- induced arthritis in mice. DBA/1 mice were immunized with bovine type II collagen and treated with rhuTNFR:Fc either from day 21 to day 28 (preventative protocol), or after disease onset for fourteen days (therapeutic protocol). Control mice received either sterile saline or human serum albumin injections. rhuT-NFR:Fc treatment significantly reduced both the incidence and the severity of collagen-induced arthritis in the preventative protocol. Mice receiving rhuTNFR:Fc therapeutically progressed to less severe disease than did control animals, and the arthritis index in rhuTNFR:Fc treated mice was significantly lower than the index in control mice from 7.5 weeks after treatment. The antibody response to collagen was significantly reduced by treatment with rhuTNFR:Fc in both the preventative and therapeutic protocols. No difference was observed in the proliferative response to type II collagen or Con A, but the response to LPS was significantly lower in rhuTNFR:Fc treated mice at the conclusion of both the preventative and therapeutic trials. The results suggest that rhuTNFR:Fc may have both immunosuppressive and antiarthritic properties in this experimental model, and may represent a useful approach to the treatment of autoimmune arthritis.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Fichtner-Feigl, M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H.-J. Schlitt, J. A. Berzofsky, and W. Strober
Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-{alpha}2
Cancer Res., May 1, 2008; 68(9): 3467 - 3475.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Zalevsky, T. Secher, S. A. Ezhevsky, L. Janot, P. M. Steed, C. O'Brien, A. Eivazi, J. Kung, D.-H. T. Nguyen, S. K. Doberstein, et al.
Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection
J. Immunol., August 1, 2007; 179(3): 1872 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. Wannamaker, R. Davies, M. Namchuk, J. Pollard, P. Ford, G. Ku, C. Decker, P. Charifson, P. Weber, U. A. Germann, et al.
(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1beta and IL-18
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 509 - 516.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
S. A. Robertson, A. S. Care, and R. J. Skinner
Interleukin 10 Regulates Inflammatory Cytokine Synthesis to Protect Against Lipopolysaccharide-Induced Abortion and Fetal Growth Restriction in Mice
Biol Reprod, May 1, 2007; 76(5): 738 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
C Plater-Zyberk, L A B Joosten, M M A Helsen, J Hepp, P A Baeuerle, and W B van den Berg
GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice
Ann Rheum Dis, April 1, 2007; 66(4): 452 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D van der Heijde, J C Da Silva, M Dougados, P Geher, I van der Horst-Bruinsma, X Juanola, I Olivieri, F Raeman, L Settas, J Sieper, et al.
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis
Ann Rheum Dis, December 1, 2006; 65(12): 1572 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Kamata, S. Kamijo, A. Nakajima, A. Koyanagi, H. Kurosawa, H. Yagita, and K. Okumura
Involvement of TNF-Like Weak Inducer of Apoptosis in the Pathogenesis of Collagen-Induced Arthritis
J. Immunol., November 1, 2006; 177(9): 6433 - 6439.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. J. Perper, B. Browning, L. C. Burkly, S. Weng, C. Gao, K. Giza, L. Su, L. Tarilonte, T. Crowell, L. Rajman, et al.
TWEAK Is a Novel Arthritogenic Mediator
J. Immunol., August 15, 2006; 177(4): 2610 - 2620.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Medicherla, J. Y. Ma, R. Mangadu, Y. Jiang, J. J. Zhao, R. Almirez, I. Kerr, E. G. Stebbins, G. O'Young, A. M. Kapoun, et al.
A Selective p38{alpha} Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 132 - 141.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P Mukherjee, S-Y Yang, B Wu, Z Song, L K Myers, P D Robbins, and P H Wooley
Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice
Ann Rheum Dis, November 1, 2005; 64(11): 1550 - 1556.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C. P. Kang, K. W. Lee, D. H. Yoo, C. Kang, and S. C. Bae
The influence of a polymorphism at position -857 of the tumour necrosis factor {alpha} gene on clinical response to etanercept therapy in rheumatoid arthritis
Rheumatology, April 1, 2005; 44(4): 547 - 552.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Cataisson, A. J. Pearson, S. Torgerson, S. A. Nedospasov, and S. H. Yuspa
Protein Kinase C{alpha}-Mediated Chemotaxis of Neutrophils Requires NF-{kappa}B Activity but Is Independent of TNF{alpha} Signaling in Mouse Skin In Vivo
J. Immunol., February 1, 2005; 174(3): 1686 - 1692.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Zhou, P. R. Mayer, J. Wajdula, and S. Fatenejad
Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis
J. Clin. Pharmacol., November 1, 2004; 44(11): 1235 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
B. Bolon, G. Campagnuolo, L. Zhu, D. Duryea, D. Zack, and U. Feige
Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} Produce Distinct, Time-dependent Patterns of Acute Arthritis in the Rat Knee
Vet. Pathol., May 1, 2004; 41(3): 235 - 243.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Zhou, A. Patat, V. Parks, M. Buckwalter, D. Metzger, and J. Korth-Bradley
Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin
J. Clin. Pharmacol., May 1, 2004; 44(5): 543 - 550.
[Abstract] [Full Text]

Home page
 Ann Rheum DisHome page
P Mukherjee, B Wu, L Mayton, S-H Kim, P D Robbins, and P H Wooley
TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis
Ann Rheum Dis, August 1, 2003; 62(8): 707 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Pandey, G. Tuncman, G. S. Hotamisligil, and F. Samad
Divergent Roles for p55 and p75 TNF-{alpha} Receptors in the Induction of Plasminogen Activator Inhibitor-1
Am. J. Pathol., March 1, 2003; 162(3): 933 - 941.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
J. A. Christopherson, E. L. Munson, D. M. England, C. L. Croke, M. C. Remington, M. L. Molitor, D. J. DeCoster, S. M. Callister, and R. F. Schell
Destructive Arthritis in Vaccinated Interferon Gamma-Deficient Mice Challenged with Borrelia burgdorferi: Modulation by Tumor Necrosis Factor Alpha
Clin. Vaccine Immunol., January 1, 2003; 10(1): 44 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
H. Ji, A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist
Critical Roles for Interleukin 1 and Tumor Necrosis Factor {alpha} in Antibody-induced Arthritis
J. Exp. Med., July 1, 2002; 196(1): 77 - 85.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. A. Mabbott, G. McGovern, M. Jeffrey, and M. E. Bruce
Temporary Blockade of the Tumor Necrosis Factor Receptor Signaling Pathway Impedes the Spread of Scrapie to the Brain
J. Virol., April 16, 2002; 76(10): 5131 - 5139.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Carballo and P. J. Blackshear
Roles of tumor necrosis factor-{alpha} receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome
Blood, October 15, 2001; 98(8): 2389 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
E. A. Burton, J. B. Wechuck, S. K. Wendell, W. F. Goins, D. J. Fink, and J. C. Glorioso
Multiple Applications For Replication-Defective Herpes Simplex Virus Vectors
Stem Cells, September 1, 2001; 19(5): 358 - 377.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. H.S. Choy and G. S. Panayi
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
N. Engl. J. Med., March 22, 2001; 344(12): 907 - 916.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
R. O. Williams, L. Marinova-Mutafchieva, M. Feldmann, and R. N. Maini
Evaluation of TNF-{alpha} and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-{alpha}/Anti-CD4 Therapy
J. Immunol., December 15, 2000; 165(12): 7240 - 7245.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Nasu, H. Kohsaka, Y. Nonomura, Y. Terada, H. Ito, K. Hirokawa, and N. Miyasaka
Adenoviral Transfer of Cyclin-Dependent Kinase Inhibitor Genes Suppresses Collagen-Induced Arthritis in Mice
J. Immunol., December 15, 2000; 165(12): 7246 - 7252.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
Y. Qian, I. Dekaris, S. Yamagami, and M. R. Dana
Topical Soluble Tumor Necrosis Factor Receptor Type I Suppresses Ocular Chemokine Gene Expression and Rejection of Allogeneic Corneal Transplants
Arch Ophthalmol, December 1, 2000; 118(12): 1666 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
G. Spencer-Green
Etanercept (Enbrel): update on therapeutic use
Ann Rheum Dis, November 1, 2000; 59(90001): i46 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
R. O Williams, M. Feldmann, and R. N Maini
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha
Ann Rheum Dis, November 1, 2000; 59(90001): i75 - 80.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
W. B van den Berg
Arguments for interleukin 1 as a target in chronic arthritis
Ann Rheum Dis, November 1, 2000; 59(90001): i81 - 84.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. Drewe, E. M. McDermott, and R. J. Powell
Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
N. Engl. J. Med., October 5, 2000; 343(14): 1044 - 1045.
[Full Text]

Home page
 Rheumatology (Oxford)Home page
T. Tomita, H. Takano, N. Tomita, R. Morishita, M. Kaneko, K. Shi, K. Takahi, T. Nakase, Y. Kaneda, H. Yoshikawa, et al.
Transcription factor decoy for NF{kappa}B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis
Rheumatology, July 1, 2000; 39(7): 749 - 757.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. A. Fox
Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis: Inhibition of Tumor Necrosis Factor
Arch Intern Med, February 28, 2000; 160(4): 437 - 444.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K.-N. Kim, S. Watanabe, Y. Ma, S. Thornton, E. H. Giannini, and R. Hirsch
Viral IL-10 and Soluble TNF Receptor Act Synergistically to Inhibit Collagen-Induced Arthritis Following Adenovirus- Mediated Gene Transfer
J. Immunol., February 1, 2000; 164(3): 1576 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. A. B. Joosten, M. M. A. Helsen, T. Saxne, F. A. J. van de Loo, and W. B. van den Berg
IL-1{alpha}{beta} Blockade Prevents Cartilage and Bone Destruction in Murine Type II Collagen-Induced Arthritis, Whereas TNF-{alpha} Blockade Only Ameliorates Joint Inflammation
J. Immunol., November 1, 1999; 163(9): 5049 - 5055.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Charles, M. J. Elliott, D. Davis, A. Potter, J. R. Kalden, C. Antoni, F. C. Breedveld, J. S. Smolen, G. Eberl, K. deWoody, et al.
Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF-{alpha} Therapy in Rheumatoid Arthritis
J. Immunol., August 1, 1999; 163(3): 1521 - 1528.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Quattrocchi, M. Walmsley, K. Browne, R. O. Williams, L. Marinova-Mutafchieva, W. Buurman, D. M. Butler, and M. Feldmann
Paradoxical Effects of Adenovirus-Mediated Blockade of TNF Activity in Murine Collagen-Induced Arthritis
J. Immunol., July 15, 1999; 163(2): 1000 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. D. Whalen, E. L. Lechman, C. A. Carlos, K. Weiss, I. Kovesdi, J. C. Glorioso, P. D. Robbins, and C. H. Evans
Adenoviral Transfer of the Viral IL-10 Gene Periarticularly to Mouse Paws Suppresses Development of Collagen-Induced Arthritis in Both Injected and Uninjected Paws
J. Immunol., March 15, 1999; 162(6): 3625 - 3632.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. Smith, S. J. Skerrett, E. Y. Chi, M. Jonas, K. Mohler, and C. B. Wilson
The locus of tumor necrosis factor-alpha action in lung inflammation.
Am. J. Respir. Cell Mol. Biol., December 1, 1998; 19(6): 881 - 891.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
J. J. Peschon, D. S. Torrance, K. L. Stocking, M. B. Glaccum, C. Otten, C. R. Willis, K. Charrier, P. J. Morrissey, C. B. Ware, and K. M. Mohler
TNF Receptor-Deficient Mice Reveal Divergent Roles for p55 and p75 in Several Models of Inflammation
J. Immunol., January 15, 1998; 160(2): 943 - 952.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. W. Moreland, S. W. Baumgartner, M. H. Schiff, E. A. Tindall, R. M. Fleischmann, A. L. Weaver, R. E. Ettlinger, S. Cohen, W. J. Koopman, K. Mohler, et al.
Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein
N. Engl. J. Med., July 17, 1997; 337(3): 141 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
I. K Campbell, A. Bendele, D. A Smith, and J. A Hamilton
Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice
Ann Rheum Dis, June 1, 1997; 56(6): 364 - 368.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
A. V. Turnbull, F. J. Pitossi, J.-J. Lebrun, S. Lee, J. C. Meltzer, D. M. Nance, A. del Rey, H. O. Besedovsky, and C. Rivier
Inhibition of Tumor Necrosis Factor-alpha Action within the CNS Markedly Reduces the Plasma Adrenocorticotropin Response to Peripheral Local Inflammation in Rats
J. Neurosci., May 1, 1997; 17(9): 3262 - 3273.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Bachmaier, C. Pummerer, I. Kozieradzki, K. Pfeffer, T. W. Mak, N. Neu, and J. M. Penninger
Low-Molecular-Weight Tumor Necrosis Factor Receptor p55 Controls Induction of Autoimmune Heart Disease
Circulation, February 4, 1997; 95(3): 655 - 661.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.